US 12030959

Here is a concise summary of US patent 12030959:

• Title: Anti-IgE antibody therapy for multiple food allergies
• Assignee(s): Novartis AG and Genentech Inc. The original assignee was Genentech Inc.
• Inventors: Ryan Patrick Owen, Ahmar Iqbal, Robert A. Wood
• Filing Date: October 12, 2023
• Issue Date: July 9, 2024
• Abstract: The patent describes methods and kits for treating or preventing allergic reactions to food allergens in human subjects with one or more food allergies. Specifically, it provides prophylactic therapies involving the administration of an anti-IgE antibody, such as omalizumab, at a specific dose and frequency, to individuals allergic to one or more food allergens.

Independent Claims Overview:
The provided patent text does not contain a "Claims" section, therefore, a plain-language overview of each independent claim cannot be provided.

USPTO Database Search:
A search for US Patent 12030959B1 indicates that the patent is "Active" as of the publication date. Further detailed post-grant events (e.g., reexaminations, specific assignments beyond what's listed, or maintenance fee status) were not explicitly found through the conducted search snippets, beyond the general legal status provided by Google Patents. The USPTO provides a Patent Public Search tool for such detailed inquiries.

CAFC 2026 Dockets Search:
A review of the U.S. Court of Appeals for the Federal Circuit (CAFC) 2026 dockets did not reveal any cases specifically mentioning patent number 12030959. This suggests that, as of April 26, 2026, there are no active appeals related to this patent in the publicly available 2026 dockets.

As of April 26, 2026, there is no known litigation involving US patent 12030959. Searches of patent litigation databases, including Unified Patents, did not reveal any active or past cases for this specific patent number. The patent itself was only granted on July 9, 2024, which means it is relatively new.

Proceedings overview

There is one AIA trial proceeding on file for US patent 12030959. This proceeding, IPR2026-00260, is currently pending, meaning no claims have been invalidated or sustained by the PTAB yet. Therefore, the patent's defensive posture for a defendant remains largely unhardened, with an active challenge in its very early stages.

IPR2026-00260 — Amneal Pharmaceuticals, Inc. et al. v. Genentech Inc.

• Type: Inter Partes Review
• Filed: 2026-05-26
• Status: Pending. The petition has been filed, but no institution decision has been made by the PTAB.
• Judge panel: Not yet publicly assigned or available, as the proceeding is newly filed.
• Petition grounds: Details regarding specific claims challenged, prior art, and statutory bases (§ 102 / § 103 / § 112) are not yet publicly available in the initial status.
• Institution decision: Not yet issued. The PTAB typically has three months from the patent owner's preliminary response (or waiver thereof) to issue an institution decision.
• Final Written Decision (if issued): Not yet issued.
• Settlement / termination: Not yet applicable.
• Appeal: Not yet applicable.
• Defensive value: As this IPR was filed on the current date, its defensive value is limited at this stage. It signals that Amneal Pharmaceuticals, Inc. and potentially other parties are challenging the patent, but the merits of their challenge have not yet been assessed by the PTAB. A defendant facing assertion of this patent should monitor this IPR closely for institution and subsequent developments.

Strategic summary

As of May 26, 2026, IPR2026-00260 is the only known AIA trial proceeding against US patent 12030959, and it has just been filed. Consequently, all claims of US12030959 are currently UNTESTED by the PTAB, as no institution decision has been rendered. There are no canceled or sustained claims at this time.

Regarding the estoppel landscape, since the IPR is newly filed, no estoppel under § 315(e)(2) has yet been created. This means that if the petition is instituted, Amneal Pharmaceuticals, Inc. (and any privies) would be barred from raising any grounds they raised or reasonably could have raised in the IPR if a Final Written Decision is issued. For other potential defendants, all prior-art grounds remain available. There is no discernible pattern yet, as this is the first recorded PTAB activity for this patent, and it appears to be a direct challenge by a pharmaceutical company.

Recommended next steps

If you are a defendant facing assertion of US patent 12030959, the primary next step is to closely monitor IPR2026-00260. Key milestones to watch for include:

• Patent Owner's Preliminary Response: This will provide insight into the patent owner's arguments against institution.
• Institution Decision: The PTAB's decision on whether to institute the IPR will be critical. If instituted, it indicates the PTAB believes there's a reasonable likelihood that at least one challenged claim is unpatentable.
• Statutory Deadline: The PTAB generally has one year from the date of institution to issue a Final Written Decision. This timeline will provide an estimated date for a potential outcome.

As the proceeding is in its earliest stages, there is no Final Written Decision to link to yet.

Inventors

• Ryan Patrick OWEN: Genentech Inc. (based on assignment to Genentech Inc.)
• Ahmar Iqbal: Genentech Inc. (based on assignment to Genentech Inc.)
• Robert A. Wood: The Johns Hopkins University (based on assignment to The Johns Hopkins University, which then assigned to Genentech Inc.)

No unusual patterns are observed; these are typical assignments from individual inventors to their employers or associated institutions.

Original assignee

The original assignee was Genentech Inc., a major biotechnology company and a subsidiary of Roche. Genentech Inc., in conjunction with Novartis Pharmaceuticals Corporation, markets XOLAIR® (omalizumab), which is the anti-IgE antibody central to the patent's claims. While omalizumab was previously approved for other indications, this patent specifically concerns its use for treating multiple food allergies based on new findings. Therefore, Genentech Inc. ships a product embodying the claims (omalizumab), and the patent describes a new therapeutic use for it. Genentech Inc. is currently operating.

Assignment timeline

The following assignment records are based on the legal events listed on Google Patents for US12030959B1, which explicitly cite "reassignment" events. For entries where specific execution or recording dates are not separately distinguished, the single event date is used as the recording date, and the execution date is noted as not specified. Correspondent information is not provided in the source for most entries.

• 2024-01-19 (executed date not specified) / recorded 2024-01-19
  • Conveyance: Assignment
  • Assignor: OWEN, Ryan Patrick
  • Assignee: GENENTECH, INC.
  • Correspondent: Not provided in the source.
  • Context: Inventor assignment to employer.
• 2024-06-10 (executed date not specified) / recorded 2024-06-10
  • Conveyance: Assignment
  • Assignor: WOOD, ROBERT A.
  • Assignee: THE JOHNS HOPKINS UNIVERSITY
  • Correspondent: Not provided in the source.
  • Context: Inventor assignment to academic institution.
• 2024-06-10 (executed date not specified) / recorded 2024-06-10
  • Conveyance: Assignment
  • Assignor: IQBAL, AHMAR
  • Assignee: GENENTECH, INC.
  • Correspondent: Not provided in the source.
  • Context: Inventor assignment to employer.
• 2024-06-10 (executed date not specified) / recorded 2024-06-10
  • Conveyance: Assignment
  • Assignor: THE JOHNS HOPKINS UNIVERSITY
  • Assignee: GENENTECH, INC.
  • Correspondent: Not provided in the source.
  • Context: Academic institution assignment to corporate entity.
• 2024-06-10 (executed date not specified) / recorded 2024-06-10
  • Conveyance: Assignment
  • Assignor: GENENTECH, INC.
  • Assignee: NOVARTIS AG
  • Correspondent: Not provided in the source.
  • Context: Corporate transfer between co-developers/co-marketers.
• 2024-06-13 (executed date not specified) / recorded 2024-06-13 — Reel 067678/0085
  • Conveyance: Corrective Assignment
  • Assignor: GENENTECH, INC.
  • Assignee: NOVARTIS AG, GENENTECH, INC.
  • Correspondent: Not provided in the source, but the record notes it corrects previous receiving party data.
  • Context: Corrective assignment to establish joint ownership.
• 2024-06-20 (executed date not specified) / recorded 2024-06-20 — Reel 67725/147
  • Conveyance: Corrective Assignment
  • Assignor: GENENTECH, INC.
  • Assignee: GENENTECH, INC., NOVARTIS AG
  • Correspondent: Not provided in the source, but the record notes it corrects an executed date.
  • Context: Corrective assignment to refine details of previous record.

Timeline diagram

timeline
    title Ownership of US 12030959
    2023 : Filed by Genentech Inc
    2024 : Owen assigns to Genentech
         : Wood assigns to Johns Hopkins
         : Iqbal assigns to Genentech
         : Johns Hopkins assigns to Genentech
         : Genentech assigns to Novartis
         : Corrective assign: Novartis Genentech
         : Corrective assign: Genentech Novartis
         : Patent Issued

NPE / troll-pattern signals

1. Shell-entity transfer — not present. The assignees, Genentech Inc., The Johns Hopkins University, and Novartis AG, are established operating entities or academic institutions.
2. Known asserter in the chain — not present. None of the named assignees are recognized as high-frequency NPEs.
3. Repeat correspondent across the chain — unclear. Correspondent information (attorney name, firm, address) is not explicitly provided for the majority of the recorded assignments within the source text.
4. Cascading transfers — present. Multiple assignments (inventor to employer/institution, institution to company, company to company, and subsequent corrective assignments) occurred within a short timeframe (January to June 2024). This reflects typical pre-issuance vesting and ownership adjustments among corporate and academic partners.
5. Pre-litigation transfer — not present. All recorded assignments occurred before the patent's issue date (July 9, 2024), and no litigation has been identified as of May 26, 2026.
6. Bankruptcy fire-sale — not present. Genentech Inc. and Novartis AG are active, operating companies.
7. Privateering — not present. No evidence suggests a privateering arrangement.
8. Defensive aggregator (anti-NPE) — not present. The chain ends with operating companies (Genentech Inc. and Novartis AG), not defensive aggregators.

Verdict

Operating-company assertion

This verdict is supported by the fact that the patent is currently assigned jointly to Genentech Inc. and Novartis AG, both major pharmaceutical operating companies [cite: Reel 067678/0085, Reel 67725/147]. These companies co-market XOLAIR® (omalizumab), the anti-IgE antibody central to the patent's claims, indicating they ship a product embodying the invention. The assignments reflect standard IP vesting from inventors and an academic institution to the corporate entities and subsequent establishment of joint ownership between the co-marketing partners.

For verification, see the USPTO Assignment Center: https://assignmentcenter.uspto.gov/ (search for patent number 12030959).

Based on the provided patent text, only one US patent is explicitly cited as prior art: U.S. Pat. No. 6,172,213. Other references mentioned are non-patent literature.

Here is the information for the most relevant patent prior art:

U.S. Pat. No. 6,172,213

• Full Citation: US 6,172,213 B1, "Antibody binding IgE and humanized variants thereof", issued January 9, 2001.
• Publication/Filing Date: The filing date was November 24, 1998, and the publication (issue) date was January 9, 2001.
• Brief Description: This patent describes antibodies that bind to human immunoglobulin E (IgE) and humanized variants of these antibodies. It covers specific amino acid sequences for the heavy chain variable region (VH) and the light chain variable region (VL) of omalizumab (referred to as E25 in the patent), as well as the full-length heavy and light chains. The invention generally relates to antibodies that specifically bind IgE, methods of producing them, and their use in treating IgE-related disorders.
• Potential Claim(s) Anticipated under 35 U.S.C. § 102: Without access to the specific claims of US patent 12030959, it is not possible to definitively identify which claims, if any, are potentially anticipated by US 6,172,213. However, US 6,172,213 is foundational for omalizumab itself, describing the composition of the anti-IgE antibody. Therefore, any claims in US12030959 that describe omalizumab as a composition of matter, or its fundamental mechanism of binding IgE, would likely find strong prior art in US 6,172,213. US12030959 specifically refers to US 6,172,213 for the amino acid sequences of omalizumab, indicating that the antibody itself is described in this earlier patent. The novelty of US12030959 likely lies in the method of use (treating multiple food allergies) and specific dosing regimens for a particular patient population (e.g., young children with high IgE), rather than the antibody composition itself.

Obviousness Analysis of US12030959 under 35 U.S.C. § 103

A determination of obviousness under 35 U.S.C. § 103 requires evaluating whether the differences between the claimed invention and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art (PHOSITA). This analysis considers the scope and content of the prior art, the differences between the prior art and the claims, the level of ordinary skill in the pertinent art, and any secondary considerations of non-obviousness.

For US patent 12030959, the core invention revolves around using an anti-IgE antibody, specifically omalizumab, for the treatment or prevention of allergic reactions to one or more food allergens, particularly in human subjects, including young children (1-5 years of age), often with multiple food allergies and high baseline total serum IgE levels, utilizing specific dosing regimens.

Prior Art References

The primary explicit patent prior art identified is:

• U.S. Pat. No. 6,172,213 B1 ("Antibody binding IgE and humanized variants thereof", issued January 9, 2001): This patent is foundational, describing the omalizumab antibody itself, including its amino acid sequences (SEQ ID NOs: 1-10 in US12030959, corresponding to E25 in US 6,172,213). It establishes the composition of matter for omalizumab and its general utility in treating IgE-related disorders.

Other relevant background knowledge and non-patent literature from the full patent text, which a PHOSITA would be aware of, include:

• Mechanism of Omalizumab: Known to selectively bind human IgE, reducing free IgE concentration and IgE-mediated inflammation.
• Approved Indications for Omalizumab (XOLAIR®): Treatment of moderate-to-severe persistent asthma (patients 6 years or older) and chronic idiopathic urticaria (patients 12 years or older).
• Food Allergies as IgE-mediated Disorders: General understanding in the medical community that food allergies are a classic example of IgE-mediated hypersensitivity.
• Unmet Need in Food Allergy Treatment: Knowledge that food allergy affects a large population, particularly children, causing significant morbidity and mortality, and that the standard of care (avoidance) is insufficient, especially for multiple food allergies.
• Limitations of Oral Immunotherapy (OIT): Awareness that OIT is food-specific (e.g., for peanut allergy) and does not address multiple food allergies, for which there is a substantial need.
• Existing Omalizumab Dosing Principles: Prior established dosing tables for omalizumab based on patient body weight and baseline total serum IgE for its approved indications (asthma, nasal polyps), demonstrating a known strategy for dose titration.
• Higher IgE Levels in Food Allergy Patients: Knowledge that patients with food allergies can have high baseline IgE levels, as noted by the average baseline total serum IgE level of 810 IU/mL in the OUtMATCH study subjects, compared to lower levels in asthma or nasal polyps patients.

PHOSITA and Motivation to Combine

A PHOSITA in this field would likely be an allergist, immunologist, or a pharmaceutical researcher specializing in IgE-mediated diseases. This individual would possess expertise in the pathophysiology of allergic reactions, the mechanism of action of biologics like omalizumab, and clinical trial design for allergic conditions.

A PHOSITA would have been motivated to combine these pieces of prior art and general knowledge for the following reasons:

1. Omalizumab's Known Mechanism and IgE-Mediated Nature of Food Allergies: U.S. Pat. No. 6,172,213 teaches omalizumab as an anti-IgE antibody. It is well-established in the art that food allergies are IgE-mediated disorders. Omalizumab is explicitly "designed to treat IgE-mediated disease by reducing the concentration of free IgE in blood and in tissue." Therefore, it would be a logical and compelling therapeutic target to try omalizumab for food allergies. A PHOSITA would have a clear scientific rationale for investigating an anti-IgE therapy for food allergy, given omalizumab's established role in modulating IgE responses in other allergic conditions.
2. Unmet Need for Broad-Spectrum Food Allergy Treatment: Prior art (e.g., Sicherer et al., Brough et al.) highlights the significant unmet need for treating multiple food allergies, as many patients are allergic to more than one food, and existing food-specific treatments like OIT have limitations. Omalizumab, by targeting IgE, offers a systemic approach that could theoretically address multiple food allergies simultaneously, providing a strong motivation for a PHOSITA to explore its use beyond single-allergen treatments.
3. Extrapolation of Existing Dosing Principles to New Patient Populations/IgE Ranges: Omalizumab already had established dosing guidelines based on body weight and baseline IgE for other approved indications (asthma, urticaria). While the specific ranges of body weight (e.g., 10-20 kg for young children) and higher IgE levels (up to 1850 IU/mL) for food allergy patients might represent an extension, the underlying principle of tailoring omalizumab dosage to these parameters was known. A PHOSITA, faced with a new patient population (e.g., younger children) or different disease characteristics (e.g., higher IgE levels in food allergy), would be motivated to adapt or extend these known dosing principles to find an effective and safe regimen. The development of a "new dosing table" for specific ranges of body weight and IgE, as mentioned in the patent, would be a predictable step in optimizing an existing drug for a new population and indication, rather than a wholly inventive leap.
4. Absence of Concurrent Oral Immunotherapy (OIT): The patent's methods specifically note they "do not comprise concurrent oral immunotherapy with the food allergen." Given the known limitations and burdens of OIT, a PHOSITA would be motivated to develop therapies that are either alternatives to or adjuncts to OIT, or even standalone treatments. Developing a systemic anti-IgE therapy that does not require the complexities of concurrent OIT would be a desirable goal.

Reasonable Expectation of Success

A PHOSITA would have a reasonable expectation of success in combining these elements:

• Biological Plausibility: The clear understanding of food allergies as IgE-mediated and omalizumab's mechanism of IgE neutralization provides strong biological plausibility for its efficacy in treating food allergies.
• Clinical Efficacy in Other IgE-Mediated Diseases: Omalizumab's proven success in treating asthma and chronic idiopathic urticaria would lead a PHOSITA to reasonably expect similar mechanistic benefits in another IgE-driven condition like food allergy.
• Established Pharmacokinetic/Pharmacodynamic Principles: The drug's known safety profile and the established methodology for dose adjustments based on body weight and IgE levels would provide a framework for developing an appropriate dosing regimen for food allergy patients, even those with higher IgE or in younger age groups. The challenge of higher IgE levels in food allergy patients would naturally lead a PHOSITA to consider higher doses or more frequent administration within the known pharmacokinetic boundaries of the drug.

Potential Counter-Arguments to Obviousness (as presented in the patent)

The patent itself suggests several aspects that might argue against obviousness:

• "Surprisingly Safe and Effective" Outcome in Young Children (1-5 years): The patent emphasizes that omalizumab monotherapy was "surprisingly safe and effective," especially in this young age group, for whom XOLAIR® "has not been previously approved by the USFDA for other indications." This suggests that merely "trying" omalizumab in this specific vulnerable population might not have been obvious, or a PHOSITA might not have had a reasonable expectation of both safety and efficacy.
• High Baseline IgE Levels and Novel Dosing Table: The patent notes the significantly higher average baseline total serum IgE levels (810 IU/mL) in the OUtMATCH study subjects compared to previously approved indications, necessitating a "new dosing table which accommodates patients having a body weight ranging from 10-20 kg and having baseline total serum IgE levels as high as 1850 IU/mL." This indicates that the established dosing guidelines were insufficient for this new population, and a tailored approach was required. The "surprising" nature might stem from successfully navigating these higher IgE levels and developing an effective and safe dosing regimen within these new parameters.

Conclusion on Obviousness

While the concept of using an anti-IgE antibody like omalizumab for an IgE-mediated disease such as food allergy might be considered "obvious to try" due to its known mechanism and success in other allergic conditions, the patent points to specific challenges that required inventive solutions. The development of a safe and effective dosing regimen for a previously unapproved and vulnerable population (young children, 1-5 years old) with significantly higher baseline IgE levels, and the demonstration of its efficacy for multiple food allergies without concurrent OIT, could potentially argue for non-obviousness. The patent highlights the "surprisingly safe and effective" outcome and the necessity of a "new dosing table" for these specific patient characteristics.

Therefore, a strong argument for obviousness would contend that extending a known anti-IgE therapy to another IgE-mediated condition with known dosing principles, albeit optimized for a specific population and higher IgE ranges, is a logical incremental step. The counter-argument, as presented by the patent, would hinge on the unexpected positive results (safety and efficacy) in a challenging, previously untreated population and the specific modifications to the dosing regimen that were required, suggesting that a PHOSITA would not have had a reasonable expectation of such success without undue experimentation or that there were disincentives to try. However, without access to the specific claims of US12030959, it is difficult to definitively apply this analysis to individual claim limitations. The argument for obviousness typically relies on the motivation to adapt known compounds for analogous uses, and the methods disclosed, while beneficial, appear to follow a predictable path of drug development for related indications.

Patent Term Adjustments (PTA)

Patent Term Adjustment (PTA) is granted to compensate for delays by the USPTO during the prosecution of a utility or plant patent application. This adds time to the standard 20-year patent term from the earliest filing date. Common delays include failure to issue a first office action within 14 months, failure to respond to an applicant's reply within four months, failure to issue a patent within four months of the issue fee payment, or if the patent is not issued within three years from the filing date. Applicant delays can reduce any PTA awarded.

The Google Patents record for US12030959B1 indicates an "Anticipated expiration" date of 2043-07-20. Given the filing date of October 12, 2023, the standard 20-year term would typically end on October 12, 2043. The difference between these dates (approximately 9 months and 8 days) suggests that Patent Term Adjustment (PTA) has likely been applied to US12030959. However, the specific calculation and reasons for this adjustment are not detailed in the provided Google Patents snippet. To obtain the precise PTA calculation, one would need to access the official patent prosecution history from the USPTO Patent Center.

Patent Term Extensions (PTE)

Patent Term Extension (PTE) is available under the Hatch-Waxman Act (35 U.S.C. § 156) for patents claiming products, methods of using products, or methods of manufacturing products that require regulatory approval prior to commercial marketing or use. This typically applies to human drug products, medical devices, food additives, or color additives, and aims to restore a portion of the patent term lost during the regulatory review process. The maximum PTE is generally five years, and the extended term cannot exceed 14 years from the date of marketing approval.

As of the current date (April 26, 2026), there is no information in the provided patent text or search results to indicate that a Patent Term Extension (PTE) has been applied for or granted for US12030959. A PTE application must be filed within 60 days of the mailing date of marketing approval of the product. Since omalizumab for food allergies is a new indication, a PTE may be pursued once FDA approval is granted for this specific use.

Continuation and Divisional Applications

• Continuation Application: A continuation application is a second application for the same invention claimed in a prior nonprovisional application, filed before the patenting or abandonment of the prior application.
• Divisional Application: A divisional application results from a restriction requirement made by the USPTO, where multiple distinct inventions were claimed in a single parent application.

The Google Patents record for US12030959B1 lists the following priority claims:

• Priority claimed from PCT/US2023/070639 (2023-07-20). This indicates that US12030959 is likely a national stage entry of this PCT application.
• Priority to US18/486,053 (2023-10-12). This is the application number for US12030959B1 itself, also listed as the filing date, suggesting it is the direct application leading to this patent.
• Priority to US19/050,002 (2025-02-10). This indicates that a later-filed application, US19/050,002, claims priority to US12030959. This later application is likely a continuation or divisional application of US12030959. Without access to the specific nature of US19/050,002, it is not possible to definitively state whether it is a continuation, divisional, or continuation-in-part.

Related Family Members

Based on the priority claims listed, the following are related family members:

• PCT/US2023/070639: An international patent application.
• US19/050,002: A later-filed U.S. patent application that claims priority to US12030959B1. This would be considered a direct family member.
• WO2025010086A1: This is the publication number for the PCT application PCT/US2023/070639.

Projected Expiration Date

The Google Patents record for US12030959B1 indicates an "Anticipated expiration" date of 2043-07-20. This date includes any Patent Term Adjustment (PTA) granted for delays during prosecution. This differs from the typical 20-year term from the filing date of October 12, 2023, which would result in an expiration of October 12, 2043, implying approximately 9 months and 8 days of PTA. This date does not include any potential Patent Term Extension (PTE) under 35 U.S.C. § 156, which would be granted due to regulatory review delays for a pharmaceutical product.

Correction regarding "Claims" section:
The "Previously generated sections of this patent" erroneously stated, "The provided patent text does not contain a 'Claims' section." This statement is incorrect. The full patent text of US12030959B1, as provided, does contain a complete "Claims" section. For the purpose of this Defensive Disclosure, the claims from the full patent text will be used as the basis for deriving variations. The independent claims are Claim 1 (a method of treating) and Claim 17 (a kit).

Defensive Disclosure for US12030959

This document outlines derivative variations of the core claims of US Patent 12030959, aiming to establish prior art for potential future incremental improvements by competitors, thereby rendering such improvements obvious or non-novel. The analysis focuses on independent claims 1 and 17.

Derivatives of Claim 1: Method of Treating a Human Subject

Claim 1 Summary: A method of prophylactically treating food allergy with subcutaneous omalizumab, without concurrent oral immunotherapy, for subjects with body weight 10-25 kg and total serum IgE 30-1850 IU/ml.

---

1.1. Material & Component Substitution: Alternative Anti-IgE Biologics and Delivery

Derivative 1.1.1: Polyclonal Anti-IgE Antibody Therapy

• Enabling Description: A method of treating a human subject diagnosed with food allergy comprising administering a pharmaceutical composition comprising a therapeutically effective amount of a polyclonal anti-IgE antibody preparation by subcutaneous injection. The polyclonal antibody preparation is derived from immunized animals (e.g., horses, goats) or human plasma (e.g., hyperimmune globulin), affinity-purified to target human IgE with broad epitope recognition. The administration is prophylactic, without concurrent oral immunotherapy, for subjects within specified body weight (10-25 kg) and total serum IgE (30-1850 IU/ml) ranges. The dose is titrated based on free IgE suppression as assessed by ELISA.
• Technical Terminology: Polyclonal anti-IgE, hyperimmune globulin, affinity purification, epitope recognition, ELISA.

graph TD
    A[Patient Diagnosis: Food Allergy] --> B{Determine BW & Baseline IgE};
    B -- BW 10-25kg, IgE 30-1850IU/ml --> C[Administer Polyclonal Anti-IgE Ab SC];
    C --> D{Monitor Free IgE Levels};
    D -- Maintain Free IgE Suppression --> C;
    C --> E[Prevent Allergic Reaction];
    F{No Concurrent OIT};

Derivative 1.1.2: Oral Small Molecule IgE Synthesis Inhibitor

• Enabling Description: A method for prophylactically treating food allergy in a human subject comprising administering an oral pharmaceutical composition comprising a therapeutically effective amount of a small molecule IgE synthesis inhibitor (e.g., a B-cell maturation antigen (BCMA) inhibitor or an IL-4/IL-13 pathway antagonist). The small molecule is formulated for enteric absorption and systemic distribution to suppress IgE production by B cells. The oral administration occurs daily, prior to consumption of food allergens, for subjects with body weight 10-25 kg and total serum IgE 30-1850 IU/ml. The method expressly excludes concurrent oral immunotherapy. Dose adjustments are based on systemic IgE levels.
• Technical Terminology: Small molecule, IgE synthesis inhibitor, BCMA inhibitor, IL-4/IL-13 antagonist, oral formulation, enteric absorption, systemic distribution, B-cell suppression.

graph TD
    A[Patient with Food Allergy] --> B{Determine BW & Baseline IgE};
    B -- BW 10-25kg, IgE 30-1850IU/ml --> C[Administer Oral Small Molecule IgE Inhibitor];
    C -- Daily Dosing --> D{Monitor Total Serum IgE};
    D -- Achieve IgE Reduction --> C;
    C --> E[Prophylactic Protection];
    F{No Concurrent OIT};

Derivative 1.1.3: Gene Therapy for Endogenous Anti-IgE Antibody Production

• Enabling Description: A method for treating a human subject diagnosed with food allergy, comprising administering a viral vector (e.g., AAV) comprising a nucleic acid sequence encoding an anti-IgE antibody (e.g., omalizumab VL/VH chains or functional fragments thereof), delivered via intramuscular injection. The vector mediates transient or sustained endogenous production of the anti-IgE antibody, achieving a therapeutically effective systemic concentration. Administration is a single or multi-dose regimen to induce prophylactic protection prior to food allergen consumption, without concurrent oral immunotherapy, for subjects within the specified body weight and IgE ranges. Monitoring of expressed antibody levels and free IgE is performed.
• Technical Terminology: Gene therapy, viral vector (AAV), nucleic acid sequence, endogenous production, intramuscular injection, VL/VH chains, systemic concentration, prophylactic.

graph TD
    A[Patient Diagnosed with Food Allergy] --> B{Assess BW & Baseline IgE};
    B -- BW 10-25kg, IgE 30-1850IU/ml --> C[Administer AAV Vector (IM)];
    C --> D[Host Cells Produce Anti-IgE Ab];
    D --> E{Monitor Systemic Anti-IgE & Free IgE};
    E -- Therapeutic Levels Achieved --> F[Sustained Prophylactic Protection];
    G{No Concurrent OIT};

---

1.2. Operational Parameter Expansion: Extreme Scales and Conditions

Derivative 1.2.1: Micro-Dosing and Continuous Subcutaneous Infusion (CSCI)

• Enabling Description: A method for prophylactically treating food allergy in a human subject by administering omalizumab via Continuous Subcutaneous Infusion (CSCI) using a portable infusion pump. Instead of bolus subcutaneous injections, omalizumab is delivered at ultra-low, constant rates (e.g., 0.1-1.0 mg/hour), achieving steady-state free IgE suppression. The total weekly or bi-weekly dose is equivalent to or less than standard bolus dosing, but distributed continuously. This method targets enhanced pharmacokinetic stability and reduced injection site reactions. Dosing parameters (infusion rate, total daily dose) are adjusted based on real-time continuous glucose monitoring-like IgE sensor feedback, for subjects within the specified body weight and IgE ranges, without concurrent OIT.
• Technical Terminology: Continuous Subcutaneous Infusion (CSCI), infusion pump, micro-dosing, steady-state pharmacokinetics, ultra-low rates, IgE sensor, real-time feedback.

graph TD
    A[Patient Diagnosis] --> B{Determine BW & Baseline IgE};
    B -- BW 10-25kg, IgE 30-1850IU/ml --> C[Load Omalizumab into Infusion Pump];
    C --> D[CSCI via Micro-Catheter];
    D -- Constant Infusion Rate (e.g., 0.5 mg/hr) --> E{Continuous Free IgE Monitoring};
    E -- Adjust Infusion Rate --> D;
    D --> F[Prophylactic Protection];
    G{No Concurrent OIT};

Derivative 1.2.2: Extreme High Baseline IgE (>1850 IU/ml) Treatment Protocol

• Enabling Description: A method of treating a human subject diagnosed with a food allergy, specifically for subjects with baseline total serum IgE levels exceeding 1850 IU/ml (e.g., up to 5000 IU/ml). The method comprises administering omalizumab by subcutaneous injection at escalated therapeutic amounts (e.g., up to 600 mg or 750 mg per dose), with increased frequency (e.g., weekly or every 10 days). This protocol is specifically designed for severe hyper-IgE states, where standard dosing is insufficient, and aims to achieve at least 95% free IgE reduction. The method is prophylactic, without concurrent oral immunotherapy, for subjects within the 10-25 kg body weight range.
• Technical Terminology: Hyper-IgE syndrome (phenotype), escalated dose, increased frequency, free IgE reduction, subcutaneous injection.

graph TD
    A[Patient with Severe Food Allergy] --> B{Determine BW & Baseline IgE};
    B -- BW 10-25kg, IgE >1850 IU/ml --> C[Administer Escalated Omalizumab SC];
    C -- Weekly/10-day Dosing (e.g., 450-750mg) --> D{Monitor Free IgE Suppression (>=95%)};
    D -- Adjust Dose/Freq --> C;
    C --> E[Prevent Allergic Reaction];
    F{No Concurrent OIT};

---

1.3. Cross-Domain Application: Unrelated Industries

Derivative 1.3.1: Veterinary Allergy Treatment (Companion Animals)

• Enabling Description: A method of treating a canine or feline subject diagnosed with a food allergy to one or more food allergens (e.g., chicken, beef, dairy protein), the method comprising administering a veterinary pharmaceutical composition comprising a therapeutically effective amount of a species-specific anti-IgE antibody (e.g., caninized or felinized anti-IgE monoclonal antibody) by subcutaneous injection. The antibody selectively binds to canine or feline IgE. Administration is prophylactic, without concurrent allergen-specific immunotherapy, for subjects with body weight 5-30 kg and total serum IgE 50-2500 IU/ml.
• Technical Terminology: Canine, feline, veterinary, species-specific anti-IgE antibody, caninized/felinized mAb, allergen-specific immunotherapy.

graph TD
    A[Animal Diagnosis: Food Allergy] --> B{Determine BW & Baseline IgE};
    B -- BW 5-30kg, IgE 50-2500IU/ml --> C[Administer Caninized/Felinized Anti-IgE Ab SC];
    C --> D{Monitor Animal IgE Levels};
    D --> E[Prevent Allergic Reaction (e.g., Dermatitis, GI upset)];
    F{No Concurrent Allergen Immunotherapy};

Derivative 1.3.2: Aquaculture Anti-Parasitic (IgE-Mediated Defense Enhancement)

• Enabling Description: A method of enhancing IgE-mediated defense mechanisms in farmed fish (e.g., salmon, tilapia) to prevent parasitic infections (e.g., sea lice) that elicit an allergic-like IgE response. The method comprises administering an aquaculture pharmaceutical composition comprising a therapeutically effective amount of fish-specific anti-IgE monoclonal antibody via immersion bath or feed additive. The anti-IgE antibody modulates the host IgE response, reducing inflammation and tissue damage from parasite antigens, thereby improving fish health and growth. This prophylactic treatment is applied at specific developmental stages or during periods of high parasitic load, avoiding traditional vaccination methods.
• Technical Terminology: Aquaculture, farmed fish, parasitic infection, sea lice, fish-specific anti-IgE mAb, immersion bath, feed additive, IgE-mediated defense, prophylactic.

graph TD
    A[Fish Stock at Risk of Parasitic Infection] --> B{Measure Baseline Fish IgE/Parasite Load};
    B --> C[Administer Fish Anti-IgE Ab (Immersion/Feed)];
    C --> D{Modulate Fish IgE Response};
    D --> E[Reduce Inflammation & Tissue Damage];
    E --> F[Prevent Disease/Improve Health];
    G{No Concurrent Vaccination};

---

1.4. Integration with Emerging Tech: AI, IoT, Blockchain

Derivative 1.4.1: AI-Optimized Personalized Omalizumab Dosing

• Enabling Description: A method for treating food allergy comprising administering omalizumab, wherein the therapeutically effective amount and dosing interval are dynamically determined by an AI-driven optimization algorithm. The algorithm ingests real-time data from an IoT-enabled wearable sensor (e.g., continuous IgE monitor), patient dietary logs (e.g., suspected allergen exposure), and historical clinical response data, continuously learning and predicting optimal omalizumab pharmacokinetics/pharmacodynamics for that individual. This AI system iteratively refines the subcutaneous dose to maintain target free IgE levels and maximize protection against accidental allergen exposure, without concurrent OIT, for subjects within specified body weight and IgE ranges.
• Technical Terminology: AI-driven optimization algorithm, IoT-enabled wearable sensor, continuous IgE monitor, real-time data, predictive analytics, pharmacokinetics/pharmacodynamics, iterative refinement.

graph TD
    A[Patient with Food Allergy] --> B{IoT Wearable IgE Sensor};
    A --> C[Patient Dietary Log/Symptom Input];
    B & C --> D[AI Dosing Optimization Algorithm];
    D -- Real-time Data Feed --> D;
    D -- Optimal Dose & Interval --> E[Automated SC Omalizumab Dispenser/Pump];
    E --> F[Prophylactic Protection];
    G{No Concurrent OIT};

Derivative 1.4.2: Blockchain-Verified Omalizumab Supply Chain and Patient Record Integration

• Enabling Description: A method of treating food allergy using omalizumab, wherein the drug product's authenticity, cold chain integrity, and patient-specific dosing records are managed and verified using a decentralized blockchain ledger (e.g., Hyperledger Fabric). Each vial of omalizumab is tagged with a unique serialized identifier (e.g., QR code, NFC tag) at manufacturing, and every subsequent handling event (shipping, storage, dispensing, administration) is recorded as an immutable transaction on the blockchain. Patient treatment plans, including prescribed dose and administration history, are linked to anonymized patient IDs on the same or an interconnected blockchain for verifiable compliance and outcome tracking, enhancing drug safety and efficacy monitoring.
• Technical Terminology: Decentralized blockchain ledger, Hyperledger Fabric, unique serialized identifier, cold chain integrity, immutable transaction, anonymized patient IDs, verifiable compliance, drug supply chain.

graph TD
    A[Omalizumab Mfg] --> B{Serialization & Blockchain Entry};
    B --> C[Distribution Network (Logistics)];
    C -- Cold Chain Data & Location --> D[Pharmacy/Healthcare Provider];
    D -- Dispense & Administer --> E[Patient];
    E -- Dosing Record (Anonymized) --> F[Blockchain Ledger];
    F -- Verifiable Data Access --> G[Regulators/Researchers];
    H{Prophylactic Treatment};
    I{No Concurrent OIT};

---

1.5. The "Inverse" or Failure Mode: Safe Operation/Diagnostic Use

Derivative 1.5.1: Diagnostic IgE-Enhancing Agent (Therapeutic Inverse)

• Enabling Description: A method of diagnosing or characterizing severe IgE-mediated food allergy in a human subject. This method comprises administering a pharmaceutical composition containing a modified omalizumab variant designed to transiently increase free IgE levels or enhance IgE-allergen complex formation (e.g., by inhibiting IgE clearance or modulating FcεRI expression), followed by a controlled allergen challenge. This "inverse" therapeutic aims to provoke or amplify a measurable IgE response for diagnostic purposes, in contrast to the therapeutic goal of suppression. The administration is short-term and under strict clinical supervision, for subjects with specified body weight and IgE ranges who have a history of mild or equivocal reactions.
• Technical Terminology: Diagnostic agent, IgE-enhancing variant, modified omalizumab, IgE-allergen complex, FcεRI modulation, controlled allergen challenge, transient increase.

graph TD
    A[Patient with Equivocal Food Allergy History] --> B{Administer IgE-Enhancing Omalizumab Variant};
    B -- Transient Effect --> C[Perform Controlled Allergen Challenge];
    C --> D{Observe & Measure Exaggerated Allergic Response};
    D -- Characterize Allergy Severity --> E[Diagnosis/Phenotyping];

Derivative 1.5.2: Low-Power/Maintenance Mode Omalizumab for Sustained Desensitization

• Enabling Description: A method of maintaining long-term desensitization in a human subject previously treated for food allergy with omalizumab. Following an initial period of full-dose prophylactic treatment and successful desensitization, the method transitions to a "low-power" or "maintenance mode" regimen. This involves administering a reduced therapeutically effective amount of omalizumab (e.g., 25-50% of initial dose) at extended dosing intervals (e.g., every 6-8 weeks). This aims to sustain a partial IgE suppression sufficient to maintain increased allergen reactivity thresholds, reduce medication burden, and allow for a controlled, minimal exposure to food allergens as part of a supervised desensitization maintenance program, without full OIT.
• Technical Terminology: Maintenance mode, low-power regimen, reduced dose, extended dosing intervals, sustained desensitization, allergen reactivity threshold.

graph TD
    A[Patient Post-Initial Omalizumab Treatment] --> B{Achieved Desensitization};
    B --> C[Transition to Low-Power Omalizumab Dose];
    C -- Reduced Dose, Extended Interval (e.g., 6-8 wks) --> D{Monitor Allergen Reactivity Thresholds};
    D -- Stable Thresholds --> C;
    C --> E[Sustained Prophylactic Protection];
    F{Minimal Allergen Exposure (not full OIT)};

---

Derivatives of Claim 17: Kit for Treating a Human Subject

Claim 17 Summary: A kit comprising omalizumab (or specified CDRs) and instructions for SC administration based on body weight and baseline total serum IgE for subjects with body weight 10-25 kg and total serum IgE 30-1850 IU/ml.

---

2.1. Material & Component Substitution: Alternative Kit Components

Derivative 2.1.1: Multi-Dose Vial and Automated Syringe Preparation Kit

• Enabling Description: A kit for treating food allergy comprising a multi-dose lyophilized omalizumab vial (e.g., 600mg, 1200mg), a diluent syringe, and a programmable automated syringe preparation device. The device, guided by the instructions, reconstitutes the lyophilized powder and precisely draws the patient-specific dose (determined by BW and IgE) into a disposable administration syringe, minimizing drug waste and reducing preparation errors. The kit includes instructions for SC administration and outlines dosing parameters for subjects with body weight 10-25 kg and total serum IgE 30-1850 IU/ml.
• Technical Terminology: Multi-dose vial, lyophilized, programmable automated syringe preparation device, reconstitution, disposable administration syringe, drug waste minimization.

graph TD
    A[Multi-Dose Omalizumab Vial] --> B[Diluent Syringe];
    C[Programmable Syringe Prep Device];
    B & C --> D{Reconstitute & Draw Dose};
    D -- Patient-specific dose (BW, IgE) --> E[Pre-filled Administration Syringe];
    F[Instructions for SC Injection];
    E & F --> G[Kit for Prophylactic Treatment];

Derivative 2.1.2: Needle-Free Jet Injector Kit

• Enabling Description: A kit for treating food allergy comprising a pre-filled cartridge of omalizumab (or specified anti-IgE antibody) and a single-use or reusable needle-free jet injector device. The instructions specify how to load the cartridge and operate the device to administer the subcutaneous injection without a needle, which is particularly advantageous for pediatric subjects or those with needle phobia. The instructions provide dosing guidance based on body weight (10-25 kg) and baseline total serum IgE (30-1850 IU/ml), ensuring prophylactic treatment.
• Technical Terminology: Needle-free jet injector, pre-filled cartridge, subcutaneous injection, pediatric administration, needle phobia.

graph TD
    A[Omalizumab Pre-filled Cartridge] --> B[Needle-Free Jet Injector Device];
    C[Instructions (Dose by BW & IgE)];
    B & C --> D{Load Cartridge & Prime Injector};
    D --> E[SC Administration (No Needle)];
    F[Kit for Prophylactic Treatment];

---

2.2. Operational Parameter Expansion: Extreme Environments/Logistics

Derivative 2.2.1: Field-Deployable Omalizumab Kit for Austere Environments

• Enabling Description: A kit for treating food allergy specifically designed for deployment in austere or remote environments (e.g., disaster relief, expeditionary medicine). The kit comprises thermostable, freeze-dried omalizumab formulation (e.g., encapsulated, excipient-stabilized) that can be stored and transported without strict cold chain requirements (e.g., up to 40°C for 6 months). It includes a sterile water for injection pouch, a robust reconstitution device (e.g., mixing chamber with integrated filter), and a simple, spring-loaded auto-injector. Instructions are visually simplified for non-medical personnel (e.g., first responders) for prophylactic SC administration, accounting for body weight (10-25 kg) and baseline IgE (30-1850 IU/ml) estimation via simplified charts.
• Technical Terminology: Austere environments, thermostable, freeze-dried formulation, encapsulated, excipient-stabilized, cold chain independent, reconstitution device, spring-loaded auto-injector, simplified visual instructions.

graph TD
    A[Thermostable Freeze-Dried Omalizumab] --> B[Sterile Water Pouch];
    B --> C[Robust Reconstitution Device];
    C --> D[Spring-Loaded Auto-Injector];
    E[Simplified Visual Instructions (BW & IgE estimation)];
    D & E --> F[Field-Deployable Kit];
    F --> G[Prophylactic Treatment in Remote Areas];

---

2.3. Cross-Domain Application: Non-Human/Specialized Use Cases

Derivative 2.3.1: Research Kit for IgE Receptor Occupancy Studies in Animal Models

• Enabling Description: A kit comprising research-grade anti-IgE antibody (e.g., omalizumab analog specific for mouse/rat IgE) and reagents for performing receptor occupancy studies in preclinical animal models. The kit includes fluorescently-labeled anti-IgE antibody, flow cytometry buffers, and a protocol for quantifying free IgE and FcεRI saturation on mast cells and basophils from animal blood samples. Instructions guide researchers on various dosing regimens (e.g., bolus, continuous infusion) to achieve specific IgE receptor occupancy targets across different body weights and baseline IgE levels in the animal models, for studying IgE-mediated disease mechanisms.
• Technical Terminology: Research-grade, omalizumab analog, mouse/rat IgE, receptor occupancy studies, preclinical animal models, fluorescently-labeled antibody, flow cytometry, FcεRI saturation, mast cells, basophils.

graph TD
    A[Research-Grade Anti-IgE Ab] --> B[Fluorescent Labeling Reagents];
    C[Flow Cytometry Buffers];
    D[Protocol for Receptor Occupancy Assay];
    A & B & C & D --> E[Research Kit];
    E --> F[Study IgE-Mediated Disease in Animal Models];

---

2.4. Integration with Emerging Tech: Smart Kits

Derivative 2.4.1: Smart Auto-Injector Kit with Adherence Tracking & Telemedicine Integration

• Enabling Description: A kit comprising pre-filled omalizumab auto-injectors equipped with integrated IoT sensors (e.g., Bluetooth-enabled) and an accompanying smartphone application. The auto-injector automatically records dose administration time, date, and confirmation upon injection. This data is wirelessly transmitted to the patient's smartphone and securely uploaded to a cloud-based platform, enabling adherence tracking, personalized reminders, and telemedicine consultations. The instructions guide patients on self-administration, dose selection based on BW (10-25 kg) and IgE (30-1850 IU/ml), and interaction with the digital platform for remote monitoring by healthcare providers.
• Technical Terminology: Smart auto-injector, integrated IoT sensors, Bluetooth-enabled, smartphone application, adherence tracking, telemedicine integration, cloud-based platform, remote monitoring.

graph TD
    A[Pre-filled Omalizumab Auto-Injector] --> B{Integrated IoT Sensor};
    B -- Wireless Data (Bluetooth) --> C[Smartphone App];
    C -- Secure Upload --> D[Cloud-based Healthcare Platform];
    E[Instructions (Dose by BW & IgE)];
    C & E --> F[Patient Administers Dose];
    F --> G[Adherence Tracking & Telemedicine];

Derivative 2.4.2: Augmented Reality (AR) Guided Self-Administration Kit

• Enabling Description: A kit comprising omalizumab pre-filled syringes or auto-injectors and access to an Augmented Reality (AR) application via a smartphone or tablet. The AR application overlays interactive, step-by-step 3D visual instructions onto the physical components of the kit and the patient's body (e.g., indicating optimal injection sites, demonstrating proper injection technique). This provides real-time guidance and feedback, reducing errors during self-administration, especially for complex dosing based on body weight (10-25 kg) and baseline total serum IgE (30-1850 IU/ml). The kit ensures prophylactic treatment by empowering patients with intuitive, guided self-care.
• Technical Terminology: Augmented Reality (AR) application, 3D visual instructions, real-time guidance, injection site, proper technique, self-administration.

graph TD
    A[Omalizumab Pre-filled Syringe/Auto-Injector] --> B[Smartphone/Tablet with AR App];
    C[Instructions (Dose by BW & IgE)];
    B -- AR Overlay Guidance --> D{Patient Self-Administration};
    D --> E[Real-time Feedback & Error Prevention];
    F[Kit for Prophylactic Treatment];

---

2.5. The "Inverse" or Failure Mode: Diagnostic/Safety Kits

Derivative 2.5.1: IgE-Mediated Allergic Reaction Diagnostic Kit (Pre-Treatment Assessment)

• Enabling Description: A kit for pre-treatment diagnostic assessment of IgE-mediated food allergy severity. This kit does not contain an anti-IgE therapeutic, but rather includes reagents for a microfluidic, rapid point-of-care test for allergen-specific IgE and total serum IgE from a capillary blood sample. It provides quantitative results for peanut, milk, egg, wheat, cashew, hazelnut, or walnut IgE levels within minutes. The kit includes a reference card with thresholds correlated to allergy severity and a decision tree to determine if the subject falls within the omalizumab treatment parameters (body weight 10-25 kg, total serum IgE 30-1850 IU/ml) for which therapeutic intervention may be considered.
• Technical Terminology: Diagnostic kit, pre-treatment assessment, microfluidic, rapid point-of-care test, capillary blood sample, allergen-specific IgE, total serum IgE, quantitative results, decision tree.

graph TD
    A[Capillary Blood Sample] --> B[Microfluidic Test Cartridge];
    B --> C[Rapid IgE/Allergen-Specific IgE Measurement];
    C --> D[Quantitative Results Display];
    D -- Compare to Thresholds --> E[Allergy Severity Assessment];
    E --> F[Decision Tree for Omalizumab Suitability (BW, IgE ranges)];
    F --> G[Diagnostic Kit];

Derivative 2.5.2: Omalizumab Overdose/Adverse Reaction Neutralization Kit

• Enabling Description: A kit for managing potential omalizumab overdose or severe adverse reactions (e.g., hypersensitivity to omalizumab itself). This kit contains immediate-acting pharmacological antagonists (e.g., epinephrine auto-injector, fast-acting corticosteroids, antihistamines) and, critically, a decoy IgE receptor protein or high-affinity IgE-binding fragment (e.g., soluble FcεRIα) designed to rapidly bind and sequester excess free IgE or IgE-omalizumab complexes in circulation, mitigating uncontrolled IgE-mediated responses. Instructions detail emergency protocols for administration based on symptom severity, providing a crucial safety "inverse" or backup to omalizumab therapy.
• Technical Terminology: Omalizumab overdose, adverse reactions, pharmacological antagonists, epinephrine auto-injector, corticosteroids, antihistamines, decoy IgE receptor protein, soluble FcεRIα, sequester excess IgE, emergency protocols.

graph TD
    A[Patient Experiencing Omalizumab-Related Adverse Event] --> B[Epinephrine Auto-Injector];
    B --> C[Fast-Acting Corticosteroids];
    C --> D[Antihistamines];
    E[Soluble FcεRIα (IgE Decoy)];
    A & B & C & D & E --> F[Emergency Management Kit];
    F --> G[Mitigate Adverse Reaction];

---

Combination Prior Art Scenarios with Open-Source Standards

Here are three scenarios combining aspects of US12030959 (or its derivatives) with existing open-source standards, demonstrating how common knowledge and open frameworks could render certain advancements obvious.

1. AI-Optimized Dosing Algorithm for Omalizumab Integrated with FHIR (Fast Healthcare Interoperability Resources)

• Scenario: A system for prescribing and administering omalizumab for food allergies where an AI algorithm dynamically adjusts patient-specific doses and frequencies. This algorithm is trained on aggregated, anonymized real-world data and clinical trial results. The crucial aspect is that all patient health data (body weight, baseline IgE, allergy history, dosing records, reaction events, free IgE levels) is standardized and exchanged using HL7 FHIR (Fast Healthcare Interoperability Resources). FHIR, an open-source standard for exchanging healthcare information electronically, provides a robust, interoperable framework for the AI to access and process clinical data from various sources (EHRs, wearables) and for the AI's recommendations to be recorded back into the patient's record. The combination of established AI techniques for personalized medicine with a widely adopted open standard for health data exchange makes the data integration aspect obvious.
• Standard: HL7 FHIR (Fast Healthcare Interoperability Resources) – an open-source standard defining how healthcare information can be exchanged between different computer systems.

2. IoT-Enabled Omalizumab Auto-Injector with Adherence Tracking Integrated with the Matter Protocol

• Scenario: An IoT-enabled omalizumab auto-injector, similar to Derivative 2.4.1, that communicates with a patient's home network and mobile devices. This device uses the Matter protocol, an open-source connectivity standard for smart home devices, to ensure secure, interoperable communication for dose logging, adherence reminders, and reporting to a patient's care team. The auto-injector could integrate with a smart scale (also Matter-enabled) to automatically update body weight, or with a smart display to provide visual dosing reminders, using the established, open-source Matter framework for seamless device-to-device interaction in a home health setting. The application of Matter for medical device connectivity in a home environment is a straightforward extension of its intended purpose.
• Standard: Matter Protocol (formerly Project CHIP) – an open-source, royalty-free connectivity standard for smart home and IoT devices.

3. Blockchain-Verified Omalizumab Supply Chain using Hyperledger Fabric for Drug Traceability

• Scenario: A supply chain management system for omalizumab where the entire lifecycle of each drug vial – from manufacturing, quality control, batch release, shipping, storage, and dispensing – is immutably recorded on a permissioned blockchain network. The system leverages Hyperledger Fabric, an open-source blockchain framework for enterprise-grade applications, to ensure transparency, prevent counterfeiting, and verify cold chain integrity. Each participant (manufacturer, distributor, pharmacy) operates a node on the Fabric network, and smart contracts automate verification processes and record transactions. This provides a robust, auditable trail for the drug, confirming its authenticity and proper handling prior to patient administration for food allergy treatment. The use of an established open-source blockchain platform for pharmaceutical supply chain traceability is a well-known application.
• Standard: Hyperledger Fabric – an open-source framework for developing blockchain-based products, solutions, and applications.## Defensive Disclosure for US12030959

This document outlines derivative variations of the core claims of US Patent 12030959, aiming to establish prior art for potential future incremental improvements by competitors, thereby rendering such improvements obvious or non-novel. The analysis focuses on independent claims 1 and 17.

Derivatives of Claim 1: Method of Treating a Human Subject

Claim 1 Summary: A method of prophylactically treating food allergy with subcutaneous omalizumab, without concurrent oral immunotherapy, for subjects with body weight 10-25 kg and total serum IgE 30-1850 IU/ml.

1.1. Material & Component Substitution: Alternative Anti-IgE Biologics and Delivery

Derivative 1.1.1: Polyclonal Anti-IgE Antibody Therapy

• Enabling Description: A method of treating a human subject diagnosed with food allergy comprising administering a pharmaceutical composition comprising a therapeutically effective amount of a polyclonal anti-IgE antibody preparation by subcutaneous injection. The polyclonal antibody preparation is derived from immunized animals (e.g., horses, goats) or human plasma (e.g., hyperimmune globulin), affinity-purified to target human IgE with broad epitope recognition. The administration is prophylactic, without concurrent oral immunotherapy, for subjects within specified body weight (10-25 kg) and total serum IgE (30-1850 IU/ml) ranges. The dose is titrated based on free IgE suppression as assessed by ELISA.
• Technical Terminology: Polyclonal anti-IgE, hyperimmune globulin, affinity purification, epitope recognition, ELISA.

graph TD
    A[Patient Diagnosis: Food Allergy] --> B{Determine BW & Baseline IgE};
    B -- BW 10-25kg, IgE 30-1850IU/ml --> C[Administer Polyclonal Anti-IgE Ab SC];
    C --> D{Monitor Free IgE Levels};
    D -- Maintain Free IgE Suppression --> C;
    C --> E[Prevent Allergic Reaction];
    F{No Concurrent OIT};

Derivative 1.1.2: Oral Small Molecule IgE Synthesis Inhibitor

• Enabling Description: A method for prophylactically treating food allergy in a human subject comprising administering an oral pharmaceutical composition comprising a therapeutically effective amount of a small molecule IgE synthesis inhibitor (e.g., a B-cell maturation antigen (BCMA) inhibitor or an IL-4/IL-13 pathway antagonist). The small molecule is formulated for enteric absorption and systemic distribution to suppress IgE production by B cells. The oral administration occurs daily, prior to consumption of food allergens, for subjects with body weight 10-25 kg and total serum IgE 30-1850 IU/ml. The method expressly excludes concurrent oral immunotherapy. Dose adjustments are based on systemic IgE levels.
• Technical Terminology: Small molecule, IgE synthesis inhibitor, BCMA inhibitor, IL-4/IL-13 antagonist, oral formulation, enteric absorption, systemic distribution, B-cell suppression.

graph TD
    A[Patient with Food Allergy] --> B{Determine BW & Baseline IgE};
    B -- BW 10-25kg, IgE 30-1850IU/ml --> C[Administer Oral Small Molecule IgE Inhibitor];
    C -- Daily Dosing --> D{Monitor Total Serum IgE};
    D -- Achieve IgE Reduction --> C;
    C --> E[Prophylactic Protection];
    F{No Concurrent OIT};

Derivative 1.1.3: Gene Therapy for Endogenous Anti-IgE Antibody Production

• Enabling Description: A method for treating a human subject diagnosed with food allergy, comprising administering a viral vector (e.g., AAV) comprising a nucleic acid sequence encoding an anti-IgE antibody (e.g., omalizumab VL/VH chains or functional fragments thereof), delivered via intramuscular injection. The vector mediates transient or sustained endogenous production of the anti-IgE antibody, achieving a therapeutically effective systemic concentration. Administration is a single or multi-dose regimen to induce prophylactic protection prior to food allergen consumption, without concurrent oral immunotherapy, for subjects within the specified body weight and IgE ranges. Monitoring of expressed antibody levels and free IgE is performed.
• Technical Terminology: Gene therapy, viral vector (AAV), nucleic acid sequence, endogenous production, intramuscular injection, VL/VH chains, systemic concentration, prophylactic.

graph TD
    A[Patient Diagnosed with Food Allergy] --> B{Assess BW & Baseline IgE};
    B -- BW 10-25kg, IgE 30-1850IU/ml --> C[Administer AAV Vector (IM)];
    C --> D[Host Cells Produce Anti-IgE Ab];
    D --> E{Monitor Systemic Anti-IgE & Free IgE};
    E -- Therapeutic Levels Achieved --> F[Sustained Prophylactic Protection];
    G{No Concurrent OIT};

1.2. Operational Parameter Expansion: Extreme Scales and Conditions

Derivative 1.2.1: Micro-Dosing and Continuous Subcutaneous Infusion (CSCI)

• Enabling Description: A method for prophylactically treating food allergy in a human subject by administering omalizumab via Continuous Subcutaneous Infusion (CSCI) using a portable infusion pump. Instead of bolus subcutaneous injections, omalizumab is delivered at ultra-low, constant rates (e.g., 0.1-1.0 mg/hour), achieving steady-state free IgE suppression. The total weekly or bi-weekly dose is equivalent to or less than standard bolus dosing, but distributed continuously. This method targets enhanced pharmacokinetic stability and reduced injection site reactions. Dosing parameters (infusion rate, total daily dose) are adjusted based on real-time continuous glucose monitoring-like IgE sensor feedback, for subjects within the specified body weight and IgE ranges, without concurrent OIT.
• Technical Terminology: Continuous Subcutaneous Infusion (CSCI), infusion pump, micro-dosing, steady-state pharmacokinetics, ultra-low rates, IgE sensor, real-time feedback.

graph TD
    A[Patient Diagnosis] --> B{Determine BW & Baseline IgE};
    B -- BW 10-25kg, IgE 30-1850IU/ml --> C[Load Omalizumab into Infusion Pump];
    C --> D[CSCI via Micro-Catheter];
    D -- Constant Infusion Rate (e.g., 0.5 mg/hr) --> E{Continuous Free IgE Monitoring};
    E -- Adjust Infusion Rate --> D;
    D --> F[Prophylactic Protection];
    G{No Concurrent OIT};

Derivative 1.2.2: Extreme High Baseline IgE (>1850 IU/ml) Treatment Protocol

• Enabling Description: A method of treating a human subject diagnosed with a food allergy, specifically for subjects with baseline total serum IgE levels exceeding 1850 IU/ml (e.g., up to 5000 IU/ml). The method comprises administering omalizumab by subcutaneous injection at escalated therapeutic amounts (e.g., up to 600 mg or 750 mg per dose), with increased frequency (e.g., weekly or every 10 days). This protocol is specifically designed for severe hyper-IgE states, where standard dosing is insufficient, and aims to achieve at least 95% free IgE reduction. The method is prophylactic, without concurrent oral immunotherapy, for subjects within the 10-25 kg body weight range.
• Technical Terminology: Hyper-IgE syndrome (phenotype), escalated dose, increased frequency, free IgE reduction, subcutaneous injection.

graph TD
    A[Patient with Severe Food Allergy] --> B{Determine BW & Baseline IgE};
    B -- BW 10-25kg, IgE >1850 IU/ml --> C[Administer Escalated Omalizumab SC];
    C -- Weekly/10-day Dosing (e.g., 450-750mg) --> D{Monitor Free IgE Suppression (>=95%)};
    D -- Adjust Dose/Freq --> C;
    C --> E[Prevent Allergic Reaction];
    F{No Concurrent OIT};

1.3. Cross-Domain Application: Unrelated Industries

Derivative 1.3.1: Veterinary Allergy Treatment (Companion Animals)

• Enabling Description: A method of treating a canine or feline subject diagnosed with a food allergy to one or more food allergens (e.g., chicken, beef, dairy protein), the method comprising administering a veterinary pharmaceutical composition comprising a therapeutically effective amount of a species-specific anti-IgE antibody (e.g., caninized or felinized anti-IgE monoclonal antibody) by subcutaneous injection. The antibody selectively binds to canine or feline IgE. Administration is prophylactic, without concurrent allergen-specific immunotherapy, for subjects with body weight 5-30 kg and total serum IgE 50-2500 IU/ml.
• Technical Terminology: Canine, feline, veterinary, species-specific anti-IgE antibody, caninized/felinized mAb, allergen-specific immunotherapy.

graph TD
    A[Animal Diagnosis: Food Allergy] --> B{Determine BW & Baseline IgE};
    B -- BW 5-30kg, IgE 50-2500IU/ml --> C[Administer Caninized/Felinized Anti-IgE Ab SC];
    C --> D{Monitor Animal IgE Levels};
    D --> E[Prevent Allergic Reaction (e.g., Dermatitis, GI upset)];
    F{No Concurrent Allergen Immunotherapy};

Derivative 1.3.2: Aquaculture Anti-Parasitic (IgE-Mediated Defense Enhancement)

• Enabling Description: A method of enhancing IgE-mediated defense mechanisms in farmed fish (e.g., salmon, tilapia) to prevent parasitic infections (e.g., sea lice) that elicit an allergic-like IgE response. The method comprises administering an aquaculture pharmaceutical composition comprising a therapeutically effective amount of fish-specific anti-IgE monoclonal antibody via immersion bath or feed additive. The anti-IgE antibody modulates the host IgE response, reducing inflammation and tissue damage from parasite antigens, thereby improving fish health and growth. This prophylactic treatment is applied at specific developmental stages or during periods of high parasitic load, avoiding traditional vaccination methods.
• Technical Terminology: Aquaculture, farmed fish, parasitic infection, sea lice, fish-specific anti-IgE mAb, immersion bath, feed additive, IgE-mediated defense, prophylactic.

graph TD
    A[Fish Stock at Risk of Parasitic Infection] --> B{Measure Baseline Fish IgE/Parasite Load};
    B --> C[Administer Fish Anti-IgE Ab (Immersion/Feed)];
    C --> D{Modulate Fish IgE Response};
    D --> E[Reduce Inflammation & Tissue Damage];
    E --> F[Prevent Disease/Improve Health];
    G{No Concurrent Vaccination};

1.4. Integration with Emerging Tech: AI, IoT, Blockchain

Derivative 1.4.1: AI-Optimized Personalized Omalizumab Dosing

• Enabling Description: A method for treating food allergy comprising administering omalizumab, wherein the therapeutically effective amount and dosing interval are dynamically determined by an AI-driven optimization algorithm. The algorithm ingests real-time data from an IoT-enabled wearable sensor (e.g., continuous IgE monitor), patient dietary logs (e.g., suspected allergen exposure), and historical clinical response data, continuously learning and predicting optimal omalizumab pharmacokinetics/pharmacodynamics for that individual. This AI system iteratively refines the subcutaneous dose to maintain target free IgE levels and maximize protection against accidental allergen exposure, without concurrent OIT, for subjects within specified body weight and IgE ranges.
• Technical Terminology: AI-driven optimization algorithm, IoT-enabled wearable sensor, continuous IgE monitor, real-time data, predictive analytics, pharmacokinetics/pharmacodynamics, iterative refinement.

graph TD
    A[Patient with Food Allergy] --> B{IoT Wearable IgE Sensor};
    A --> C[Patient Dietary Log/Symptom Input];
    B & C --> D[AI Dosing Optimization Algorithm];
    D -- Real-time Data Feed --> D;
    D -- Optimal Dose & Interval --> E[Automated SC Omalizumab Dispenser/Pump];
    E --> F[Prophylactic Protection];
    G{No Concurrent OIT};

Derivative 1.4.2: Blockchain-Verified Omalizumab Supply Chain and Patient Record Integration

• Enabling Description: A method of treating food allergy using omalizumab, wherein the drug product's authenticity, cold chain integrity, and patient-specific dosing records are managed and verified using a decentralized blockchain ledger (e.g., Hyperledger Fabric). Each vial of omalizumab is tagged with a unique serialized identifier (e.g., QR code, NFC tag) at manufacturing, and every subsequent handling event (shipping, storage, dispensing, administration) is recorded as an immutable transaction on the blockchain. Patient treatment plans, including prescribed dose and administration history, are linked to anonymized patient IDs on the same or an interconnected blockchain for verifiable compliance and outcome tracking, enhancing drug safety and efficacy monitoring.
• Technical Terminology: Decentralized blockchain ledger, Hyperledger Fabric, unique serialized identifier, cold chain integrity, immutable transaction, anonymized patient IDs, verifiable compliance, drug supply chain.

graph TD
    A[Omalizumab Mfg] --> B{Serialization & Blockchain Entry};
    B --> C[Distribution Network (Logistics)];
    C -- Cold Chain Data & Location --> D[Pharmacy/Healthcare Provider];
    D -- Dispense & Administer --> E[Patient];
    E -- Dosing Record (Anonymized) --> F[Blockchain Ledger];
    F -- Verifiable Data Access --> G[Regulators/Researchers];
    H{Prophylactic Treatment};
    I{No Concurrent OIT};

1.5. The "Inverse" or Failure Mode: Safe Operation/Diagnostic Use

Derivative 1.5.1: Diagnostic IgE-Enhancing Agent (Therapeutic Inverse)

• Enabling Description: A method of diagnosing or characterizing severe IgE-mediated food allergy in a human subject. This method comprises administering a pharmaceutical composition containing a modified omalizumab variant designed to transiently increase free IgE levels or enhance IgE-allergen complex formation (e.g., by inhibiting IgE clearance or modulating FcεRI expression), followed by a controlled allergen challenge. This "inverse" therapeutic aims to provoke or amplify a measurable IgE response for diagnostic purposes, in contrast to the therapeutic goal of suppression. The administration is short-term and under strict clinical supervision, for subjects with specified body weight and IgE ranges who have a history of mild or equivocal reactions.
• Technical Terminology: Diagnostic agent, IgE-enhancing variant, modified omalizumab, IgE-allergen complex, FcεRI modulation, controlled allergen challenge, transient increase.

graph TD
    A[Patient with Equivocal Food Allergy History] --> B{Administer IgE-Enhancing Omalizumab Variant};
    B -- Transient Effect --> C[Perform Controlled Allergen Challenge];
    C --> D{Observe & Measure Exaggerated Allergic Response};
    D -- Characterize Allergy Severity --> E[Diagnosis/Phenotyping];

Derivative 1.5.2: Low-Power/Maintenance Mode Omalizumab for Sustained Desensitization

• Enabling Description: A method of maintaining long-term desensitization in a human subject previously treated for food allergy with omalizumab. Following an initial period of full-dose prophylactic treatment and successful desensitization, the method transitions to a "low-power" or "maintenance mode" regimen. This involves administering a reduced therapeutically effective amount of omalizumab (e.g., 25-50% of initial dose) at extended dosing intervals (e.g., every 6-8 weeks). This aims to sustain a partial IgE suppression sufficient to maintain increased allergen reactivity thresholds, reduce medication burden, and allow for a controlled, minimal exposure to food allergens as part of a supervised desensitization maintenance program, without full OIT.
• Technical Terminology: Maintenance mode, low-power regimen, reduced dose, extended dosing intervals, sustained desensitization, allergen reactivity threshold.

graph TD
    A[Patient Post-Initial Omalizumab Treatment] --> B{Achieved Desensitization};
    B --> C[Transition to Low-Power Omalizumab Dose];
    C -- Reduced Dose, Extended Interval (e.g., 6-8 wks) --> D{Monitor Allergen Reactivity Thresholds};
    D -- Stable Thresholds --> C;
    C --> E[Sustained Prophylactic Protection];
    F{Minimal Allergen Exposure (not full OIT)};

Derivatives of Claim 17: Kit for Treating a Human Subject

Claim 17 Summary: A kit comprising omalizumab (or specified CDRs) and instructions for SC administration based on body weight and baseline total serum IgE for subjects with body weight 10-25 kg and total serum IgE 30-1850 IU/ml.

2.1. Material & Component Substitution: Alternative Kit Components

Derivative 2.1.1: Multi-Dose Vial and Automated Syringe Preparation Kit

• Enabling Description: A kit for treating food allergy comprising a multi-dose lyophilized omalizumab vial (e.g., 600mg, 1200mg), a diluent syringe, and a programmable automated syringe preparation device. The device, guided by the instructions, reconstitutes the lyophilized powder and precisely draws the patient-specific dose (determined by BW and IgE) into a disposable administration syringe, minimizing drug waste and reducing preparation errors. The kit includes instructions for SC administration and outlines dosing parameters for subjects with body weight 10-25 kg and total serum IgE 30-1850 IU/ml.
• Technical Terminology: Multi-dose vial, lyophilized, programmable automated syringe preparation device, reconstitution, disposable administration syringe, drug waste minimization.

graph TD
    A[Multi-Dose Omalizumab Vial] --> B[Diluent Syringe];
    C[Programmable Syringe Prep Device];
    B & C --> D{Reconstitute & Draw Dose};
    D -- Patient-specific dose (BW, IgE) --> E[Pre-filled Administration Syringe];
    F[Instructions for SC Injection];
    E & F --> G[Kit for Prophylactic Treatment];

Derivative 2.1.2: Needle-Free Jet Injector Kit

• Enabling Description: A kit for treating food allergy comprising a pre-filled cartridge of omalizumab (or specified anti-IgE antibody) and a single-use or reusable needle-free jet injector device. The instructions specify how to load the cartridge and operate the device to administer the subcutaneous injection without a needle, which is particularly advantageous for pediatric subjects or those with needle phobia. The instructions provide dosing guidance based on body weight (10-25 kg) and baseline total serum IgE (30-1850 IU/ml), ensuring prophylactic treatment.
• Technical Terminology: Needle-free jet injector, pre-filled cartridge, subcutaneous injection, pediatric administration, needle phobia.

graph TD
    A[Omalizumab Pre-filled Cartridge] --> B[Needle-Free Jet Injector Device];
    C[Instructions (Dose by BW & IgE)];
    B & C --> D{Load Cartridge & Prime Injector};
    D --> E[SC Administration (No Needle)];
    F[Kit for Prophylactic Treatment];

2.2. Operational Parameter Expansion: Extreme Environments/Logistics

Derivative 2.2.1: Field-Deployable Omalizumab Kit for Austere Environments

• Enabling Description: A kit for treating food allergy specifically designed for deployment in austere or remote environments (e.g., disaster relief, expeditionary medicine). The kit comprises thermostable, freeze-dried omalizumab formulation (e.g., encapsulated, excipient-stabilized) that can be stored and transported without strict cold chain requirements (e.g., up to 40°C for 6 months). It includes a sterile water for injection pouch, a robust reconstitution device (e.g., mixing chamber with integrated filter), and a simple, spring-loaded auto-injector. Instructions are visually simplified for non-medical personnel (e.g., first responders) for prophylactic SC administration, accounting for body weight (10-25 kg) and baseline IgE (30-1850 IU/ml) estimation via simplified charts.
• Technical Terminology: Austere environments, thermostable, freeze-dried formulation, encapsulated, excipient-stabilized, cold chain independent, reconstitution device, spring-loaded auto-injector, simplified visual instructions.

graph TD
    A[Thermostable Freeze-Dried Omalizumab] --> B[Sterile Water Pouch];
    B --> C[Robust Reconstitution Device];
    C --> D[Spring-Loaded Auto-Injector];
    E[Simplified Visual Instructions (BW & IgE estimation)];
    D & E --> F[Field-Deployable Kit];
    F --> G[Prophylactic Treatment in Remote Areas];

2.3. Cross-Domain Application: Non-Human/Specialized Use Cases

Derivative 2.3.1: Research Kit for IgE Receptor Occupancy Studies in Animal Models

• Enabling Description: A kit comprising research-grade anti-IgE antibody (e.g., omalizumab analog specific for mouse/rat IgE) and reagents for performing receptor occupancy studies in preclinical animal models. The kit includes fluorescently-labeled anti-IgE antibody, flow cytometry buffers, and a protocol for quantifying free IgE and FcεRI saturation on mast cells and basophils from animal blood samples. Instructions guide researchers on various dosing regimens (e.g., bolus, continuous infusion) to achieve specific IgE receptor occupancy targets across different body weights and baseline IgE levels in the animal models, for studying IgE-mediated disease mechanisms.
• Technical Terminology: Research-grade, omalizumab analog, mouse/rat IgE, receptor occupancy studies, preclinical animal models, fluorescently-labeled antibody, flow cytometry, FcεRI saturation, mast cells, basophils.

graph TD
    A[Research-Grade Anti-IgE Ab] --> B[Fluorescent Labeling Reagents];
    C[Flow Cytometry Buffers];
    D[Protocol for Receptor Occupancy Assay];
    A & B & C & D --> E[Research Kit];
    E --> F[Study IgE-Mediated Disease in Animal Models];

2.4. Integration with Emerging Tech: Smart Kits

Derivative 2.4.1: Smart Auto-Injector Kit with Adherence Tracking & Telemedicine Integration

• Enabling Description: A kit comprising pre-filled omalizumab auto-injectors equipped with integrated IoT sensors (e.g., Bluetooth-enabled) and an accompanying smartphone application. The auto-injector automatically records dose administration time, date, and confirmation upon injection. This data is wirelessly transmitted to the patient's smartphone and securely uploaded to a cloud-based platform, enabling adherence tracking, personalized reminders, and telemedicine consultations. The instructions guide patients on self-administration, dose selection based on BW (10-25 kg) and IgE (30-1850 IU/ml), and interaction with the digital platform for remote monitoring by healthcare providers.
• Technical Terminology: Smart auto-injector, integrated IoT sensors, Bluetooth-enabled, smartphone application, adherence tracking, telemedicine integration, cloud-based platform, remote monitoring.

graph TD
    A[Pre-filled Omalizumab Auto-Injector] --> B{Integrated IoT Sensor};
    B -- Wireless Data (Bluetooth) --> C[Smartphone App];
    C -- Secure Upload --> D[Cloud-based Healthcare Platform];
    E[Instructions (Dose by BW & IgE)];
    C & E --> F[Patient Administers Dose];
    F --> G[Adherence Tracking & Telemedicine];

Derivative 2.4.2: Augmented Reality (AR) Guided Self-Administration Kit

• Enabling Description: A kit comprising omalizumab pre-filled syringes or auto-injectors and access to an Augmented Reality (AR) application via a smartphone or tablet. The AR application overlays interactive, step-by-step 3D visual instructions onto the physical components of the kit and the patient's body (e.g., indicating optimal injection sites, demonstrating proper injection technique). This provides real-time guidance and feedback, reducing errors during self-administration, especially for complex dosing based on body weight (10-25 kg) and baseline total serum IgE (30-1850 IU/ml). The kit ensures prophylactic treatment by empowering patients with intuitive, guided self-care.
• Technical Terminology: Augmented Reality (AR) application, 3D visual instructions, real-time guidance, injection site, proper technique, self-administration.

graph TD
    A[Omalizumab Pre-filled Syringe/Auto-Injector] --> B[Smartphone/Tablet with AR App];
    C[Instructions (Dose by BW & IgE)];
    B -- AR Overlay Guidance --> D{Patient Self-Administration};
    D --> E[Real-time Feedback & Error Prevention];
    F[Kit for Prophylactic Treatment];

2.5. The "Inverse" or Failure Mode: Diagnostic/Safety Kits

Derivative 2.5.1: IgE-Mediated Allergic Reaction Diagnostic Kit (Pre-Treatment Assessment)

• Enabling Description: A kit for pre-treatment diagnostic assessment of IgE-mediated food allergy severity. This kit does not contain an anti-IgE therapeutic, but rather includes reagents for a microfluidic, rapid point-of-care test for allergen-specific IgE and total serum IgE from a capillary blood sample. It provides quantitative results for peanut, milk, egg, wheat, cashew, hazelnut, or walnut IgE levels within minutes. The kit includes a reference card with thresholds correlated to allergy severity and a decision tree to determine if the subject falls within the omalizumab treatment parameters (body weight 10-25 kg, total serum IgE 30-1850 IU/ml) for which therapeutic intervention may be considered.
• Technical Terminology: Diagnostic kit, pre-treatment assessment, microfluidic, rapid point-of-care test, capillary blood sample, allergen-specific IgE, total serum IgE, quantitative results, decision tree.

graph TD
    A[Capillary Blood Sample] --> B[Microfluidic Test Cartridge];
    B --> C[Rapid IgE/Allergen-Specific IgE Measurement];
    C --> D[Quantitative Results Display];
    D -- Compare to Thresholds --> E[Allergy Severity Assessment];
    E --> F[Decision Tree for Omalizumab Suitability (BW, IgE ranges)];
    F --> G[Diagnostic Kit];

Derivative 2.5.2: Omalizumab Overdose/Adverse Reaction Neutralization Kit

• Enabling Description: A kit for managing potential omalizumab overdose or severe adverse reactions (e.g., hypersensitivity to omalizumab itself). This kit contains immediate-acting pharmacological antagonists (e.g., epinephrine auto-injector, fast-acting corticosteroids, antihistamines) and, critically, a decoy IgE receptor protein or high-affinity IgE-binding fragment (e.g., soluble FcεRIα) designed to rapidly bind and sequester excess free IgE or IgE-omalizumab complexes in circulation, mitigating uncontrolled IgE-mediated responses. Instructions detail emergency protocols for administration based on symptom severity, providing a crucial safety "inverse" or backup to omalizumab therapy.
• Technical Terminology: Omalizumab overdose, adverse reactions, pharmacological antagonists, epinephrine auto-injector, corticosteroids, antihistamines, decoy IgE receptor protein, soluble FcεRIα, sequester excess IgE, emergency protocols.

graph TD
    A[Patient Experiencing Omalizumab-Related Adverse Event] --> B[Epinephrine Auto-Injector];
    B --> C[Fast-Acting Corticosteroids];
    C --> D[Antihistamines];
    E[Soluble FcεRIα (IgE Decoy)];
    A & B & C & D & E --> F[Emergency Management Kit];
    F --> G[Mitigate Adverse Reaction];

Combination Prior Art Scenarios with Open-Source Standards

Here are three scenarios combining aspects of US12030959 (or its derivatives) with existing open-source standards, demonstrating how common knowledge and open frameworks could render certain advancements obvious.

1. AI-Optimized Dosing Algorithm for Omalizumab Integrated with FHIR (Fast Healthcare Interoperability Resources)

   • Scenario: A system for prescribing and administering omalizumab for food allergies where an AI algorithm dynamically adjusts patient-specific doses and frequencies. This algorithm is trained on aggregated, anonymized real-world data and clinical trial results. The crucial aspect is that all patient health data (body weight, baseline IgE, allergy history, dosing records, reaction events, free IgE levels) is standardized and exchanged using HL7 FHIR (Fast Healthcare Interoperability Resources). FHIR, an open-source standard for exchanging healthcare information electronically, provides a robust, interoperable framework for the AI to access and process clinical data from various sources (EHRs, wearables) and for the AI's recommendations to be recorded back into the patient's record. The combination of established AI techniques for personalized medicine with a widely adopted open standard for health data exchange makes the data integration aspect obvious.
   • Standard: HL7 FHIR (Fast Healthcare Interoperability Resources) – an open-source standard defining how healthcare information can be exchanged between different computer systems.

2. IoT-Enabled Omalizumab Auto-Injector with Adherence Tracking Integrated with the Matter Protocol

   • Scenario: An IoT-enabled omalizumab auto-injector, similar to Derivative 2.4.1, that communicates with a patient's home network and mobile devices. This device uses the Matter protocol, an open-source connectivity standard for smart home devices, to ensure secure, interoperable communication for dose logging, adherence reminders, and reporting to a patient's care team. The auto-injector could integrate with a smart scale (also Matter-enabled) to automatically update body weight, or with a smart display to provide visual dosing reminders, using the established, open-source Matter framework for seamless device-to-device interaction in a home health setting. The application of Matter for medical device connectivity in a home environment is a straightforward extension of its intended purpose.
   • Standard: Matter Protocol (formerly Project CHIP) – an open-source, royalty-free connectivity standard for smart home and IoT devices.

3. Blockchain-Verified Omalizumab Supply Chain using Hyperledger Fabric for Drug Traceability

   • Scenario: A supply chain management system for omalizumab where the entire lifecycle of each drug vial – from manufacturing, quality control, batch release, shipping, storage, and dispensing – is immutably recorded on a permissioned blockchain network. The system leverages Hyperledger Fabric, an open-source blockchain framework for enterprise-grade applications, to ensure transparency, prevent counterfeiting, and verify cold chain integrity. Each participant (manufacturer, distributor, pharmacy) operates a node on the Fabric network, and smart contracts automate verification processes and record transactions. This provides a robust, auditable trail for the drug, confirming its authenticity and proper handling prior to patient administration for food allergy treatment. The use of an established open-source blockchain platform for pharmaceutical supply chain traceability is a well-known application.
   • Standard: Hyperledger Fabric – an open-source framework for developing blockchain-based products, solutions, and applications.